AstraZeneca has been cleared to include cardiovascular and kidney outcomes data on the label of its type 2 diabetes therapy Forxiga in the EU which could help it challenge rival drugs in the SGLT2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback